⌘K
t
Faron Pharmaceuticals Ltd. announced on 8 April 2022 that its Chief Executive Officer, Dr. Markku Jalkanen, acquired 25,000 ordinary shares in the company on 5 April 2022. These shares were purchased at a volume weighted average price of €2.8213 per share. Following this transaction, Dr. Jalkanen directly holds 2,125,565 ordinary shares (3.99% of issued share capital) and has a combined interest with his spouse of 3,251,677 ordinary shares (6.11%).
| Date | 8 Apr 2022 |
| Time | 15:45:08 |
| Category | Director/PDMR dealings |
| ID | 8489H |
Faron Pharmaceuticals Ltd.
("Faron" or the "Company")
Managers' transactions
Company announcement, 8 April 2022 at 5:45 PM (EET) / 3:45 PM (GMT) / 10:45 AM (EDT)
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces today that Dr Markku Jalkanen, Chief Executive Officer of the Company, acquired 25,000 ordinary shares in Faron at a volume weighted average price of €2.8213 per share on 5 April, 2022. Following these purchases, Dr Jalkanen directly holds 2,125,565 ordinary shares in the Company, representing 3.99 per cent. of the Company's issued share capital and has a combined interest with his spouse in 3,251,677 ordinary shares in the Company, representing 6.11 per cent of the Company's issued share capital.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
Markku Jalkanen |
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
Chief Executive Officer |
||||||
|
b. |
Initial notification/ Amendment |
Initial Notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
Faron Pharmaceuticals Oy |
||||||
|
b. |
LEI |
7437009H31TO1DC0EB42 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares |
||||||
|
b. |
Nature of the transaction |
Purchase of ordinary shares |
||||||
|
c. |
Price(s) and volume(s) |
|
Average |
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
€2.8213 |
25,000 |
|
||||||
|
Transaction details (1): Volume: 91 Unit price: 2.84 EUR (2): Volume: 167 Unit price: 2.825 EUR (3): Volume: 192 Unit price: 2.825 EUR (4): Volume: 16 Unit price: 2.825 EUR (5): Volume: 16 Unit price: 2.825 EUR (6): Volume: 509 Unit price: 2.825 EUR (7): Volume: 40 Unit price: 2.825 EUR (8): Volume: 116 Unit price: 2.825 EUR (9): Volume: 129 Unit price: 2.825 EUR (10): Volume: 688 Unit price: 2.825 EUR (11): Volume: 192 Unit price: 2.825 EUR (12): Volume: 167 Unit price: 2.825 EUR (13): Volume: 16 Unit price: 2.825 EUR (14): Volume: 132 Unit price: 2.825 EUR (15): Volume: 169 Unit price: 2.825 EUR (16): Volume: 1,063 Unit price: 2.825 EUR (17): Volume: 175 Unit price: 2.825 EUR (18): Volume: 283 Unit price: 2.825 EUR (19): Volume: 889 Unit price: 2.82 EUR (20): Volume: 97 Unit price: 2.82 EUR (21): Volume: 466 Unit price: 2.8 EUR (22): Volume: 1,487 Unit price: 2.8 EUR (23): Volume: 1,267 Unit price: 2.8 EUR (24): Volume: 97 Unit price: 2.8 EUR (25): Volume: 1,267 Unit price: 2.8 EUR (26): Volume: 206 Unit price: 2.8 EUR (27): Volume: 77 Unit price: 2.82 EUR (28): Volume: 153 Unit price: 2.82 EUR (29): Volume: 40 Unit price: 2.82 EUR (30): Volume: 77 Unit price: 2.82 EUR (31): Volume: 14 Unit price: 2.82 EUR (32): Volume: 100 Unit price: 2.82 EUR (33): Volume: 17 Unit price: 2.82 EUR (34): Volume: 139 Unit price: 2.82 EUR (35): Volume: 14 Unit price: 2.82 EUR (36): Volume: 184 Unit price: 2.82 EUR (37): Volume: 55 Unit price: 2.82 EUR (38): Volume: 31 Unit price: 2.82 EUR (39): Volume: 55 Unit price: 2.82 EUR (40): Volume: 129 Unit price: 2.82 EUR (41): Volume: 86 Unit price: 2.82 EUR (42): Volume: 55 Unit price: 2.82 EUR (43): Volume: 98 Unit price: 2.82 EUR (44): Volume: 117 Unit price: 2.82 EUR (45): Volume: 153 Unit price: 2.82 EUR (46): Volume: 117 Unit price: 2.82 EUR (47): Volume: 153 Unit price: 2.82 EUR (48): Volume: 17 Unit price: 2.82 EUR (49): Volume: 100 Unit price: 2.82 EUR (50): Volume: 69 Unit price: 2.82 EUR (51): Volume: 184 Unit price: 2.82 EUR (52): Volume: 86 Unit price: 2.82 EUR (53): Volume: 86 Unit price: 2.82 EUR (54): Volume: 184 Unit price: 2.82 EUR (55): Volume: 98 Unit price: 2.82 EUR (56): Volume: 270 Unit price: 2.82 EUR (57): Volume: 270 Unit price: 2.82 EUR (58): Volume: 100 Unit price: 2.82 EUR (59): Volume: 270 Unit price: 2.82 EUR (60): Volume: 270 Unit price: 2.82 EUR (61): Volume: 68 Unit price: 2.835 EUR (62): Volume: 25 Unit price: 2.835 EUR (63): Volume: 17 Unit price: 2.835 EUR (64): Volume: 104 Unit price: 2.835 EUR (65): Volume: 43 Unit price: 2.835 EUR (66): Volume: 85 Unit price: 2.835 EUR (67): Volume: 14 Unit price: 2.835 EUR (68): Volume: 31 Unit price: 2.835 EUR (69): Volume: 18 Unit price: 2.835 EUR (70): Volume: 71 Unit price: 2.835 EUR (71): Volume: 9 Unit price: 2.835 EUR (72): Volume: 104 Unit price: 2.835 EUR (73): Volume: 31 Unit price: 2.835 EUR (74): Volume: 47 Unit price: 2.835 EUR (75): Volume: 89 Unit price: 2.835 EUR (76): Volume: 76 Unit price: 2.835 EUR (77): Volume: 75 Unit price: 2.835 EUR (78): Volume: 21 Unit price: 2.835 EUR (79): Volume: 10 Unit price: 2.835 EUR (80): Volume: 68 Unit price: 2.835 EUR (81): Volume: 97 Unit price: 2.835 EUR (82): Volume: 75 Unit price: 2.835 EUR (83): Volume: 75 Unit price: 2.835 EUR (84): Volume: 43 Unit price: 2.835 EUR (85): Volume: 85 Unit price: 2.835 EUR (86): Volume: 68 Unit price: 2.835 EUR (87): Volume: 143 Unit price: 2.835 EUR (88): Volume: 85 Unit price: 2.835 EUR (89): Volume: 43 Unit price: 2.835 EUR (90): Volume: 9 Unit price: 2.835 EUR (91): Volume: 71 Unit price: 2.835 EUR (92): Volume: 18 Unit price: 2.835 EUR (93): Volume: 135 Unit price: 2.835 EUR (94): Volume: 47 Unit price: 2.835 EUR (95): Volume: 89 Unit price: 2.835 EUR (96): Volume: 182 Unit price: 2.835 EUR (97): Volume: 21 Unit price: 2.835 EUR (98): Volume: 68 Unit price: 2.835 EUR (99): Volume: 97 Unit price: 2.835 EUR (100): Volume: 153 Unit price: 2.835 EUR (101): Volume: 75 Unit price: 2.835 EUR (102): Volume: 43 Unit price: 2.835 EUR (103): Volume: 228 Unit price: 2.835 EUR (104): Volume: 43 Unit price: 2.835 EUR (105): Volume: 94 Unit price: 2.835 EUR (106): Volume: 71 Unit price: 2.835 EUR (107): Volume: 147 Unit price: 2.835 EUR (108): Volume: 6 Unit price: 2.835 EUR (109): Volume: 47 Unit price: 2.835 EUR (110): Volume: 271 Unit price: 2.835 EUR (111): Volume: 68 Unit price: 2.835 EUR (112): Volume: 271 Unit price: 2.835 EUR (113): Volume: 75 Unit price: 2.835 EUR (114): Volume: 271 Unit price: 2.835 EUR (115): Volume: 143 Unit price: 2.835 EUR (116): Volume: 71 Unit price: 2.835 EUR (117): Volume: 147 Unit price: 2.835 EUR (118): Volume: 918 Unit price: 2.835 EUR (119): Volume: 175 Unit price: 2.835 EUR (120): Volume: 73 Unit price: 2.815 EUR (121): Volume: 358 Unit price: 2.8 EUR (122): Volume: 168 Unit price: 2.8 EUR (123): Volume: 129 Unit price: 2.8 EUR (124): Volume: 120 Unit price: 2.835 EUR (125): Volume: 103 Unit price: 2.835 EUR (126): Volume: 272 Unit price: 2.835 EUR (127): Volume: 58 Unit price: 2.835 EUR (128): Volume: 133 Unit price: 2.835 EUR (129): Volume: 803 Unit price: 2.835 EUR (130): Volume: 1,034 Unit price: 2.835 EUR (131): Volume: 167 Unit price: 2.83 EUR (132): Volume: 79 Unit price: 2.83 EUR (133): Volume: 137 Unit price: 2.83 EUR (134): Volume: 51 Unit price: 2.82 EUR (135): Volume: 46 Unit price: 2.82 EUR (136): Volume: 68 Unit price: 2.82 EUR (137): Volume: 541 Unit price: 2.82 EUR (138): Volume: 200 Unit price: 2.82 EUR (139): Volume: 200 Unit price: 2.82 EUR (140): Volume: 400 Unit price: 2.81 EUR (141): Volume: 8 Unit price: 2.8 EUR (142): Volume: 14 Unit price: 2.8 EUR (143): Volume: 27 Unit price: 2.8 EUR (144): Volume: 7 Unit price: 2.8 EUR (145): Volume: 85 Unit price: 2.8 EUR (146): Volume: 43 Unit price: 2.8 EUR (147): Volume: 71 Unit price: 2.8 EUR (148): Volume: 4 Unit price: 2.8 EUR (149): Volume: 22 Unit price: 2.8 EUR
|
||||||||
|
d. |
Aggregated information
- Aggregated Volume
- Price
|
25,000
Volume weighted average price of €2.8213 |
||||||
|
e. |
Date of the transaction |
5 April, 2022 |
||||||
|
f. |
Place of the transaction |
Nasdaq First North Growth Market |
||||||
For more information please contact:
Media / Investor Contact
Faron Pharmaceuticals
Eric Van Zanten
Head of Communications
investor.relations@faron.com
Phone: +1 (610) 529-6219
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.